Cenersen, An Antisense Inhibitor of p53, in Combination with Fludarabine, Cyclophosphamide, and Rituximab Shows Clinical Activity in High Risk CLL.

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Lanasa, MC; Davis, PH; Datto, M; Cook, H; Rizzieri, DA

Published Date

  • November 20, 2009

Published In

Volume / Issue

  • 114 / 22

Start / End Page

  • 1332 - 1332

Published By

Pages

  • 1

International Standard Serial Number (ISSN)

  • 0006-4971

Conference Name

  • 51st Annual Meeting of the American-Society-of-Hematology

Conference Location

  • New Orleans, LA

Conference Start Date

  • December 5, 2009

Conference End Date

  • December 8, 2009